Renalytix And 2 British AI Healthcare Stocks To Watch
November 8, 20264 Mins read12
Share
Banks in the UK are already drawing hard lines around AI agents, with major lenders blocking automated tools from touching customer accounts. That kind of caution highlights how powerful these systems are becoming. For investors, the bigger story is that the same technology is being built into healthcare to sift scans, notes, and lab data at huge scale. This article runs through three UK listed AI healthcare stocks from our screener that tap into that shift.
The three stocks below are a starter set from this idea. The full screen surfaced six more UK listed healthcare AI companies with equally compelling stories that are not covered here. To see the full list and quickly identify your own highest conviction opportunities, head into the Transformative Artificial intelligence (AI) Healthcare Stocks screener.
Renalytix is a London based diagnostics business that applies artificial intelligence to kidney disease, using its KidneyIntelX platform to combine biomarkers, genetics, and electronic health records into risk scores used in clinics and drug trials. It currently generates about $3 million from healthcare software and has a market value near £33 million.
Renalytix ties directly into the healthcare AI theme because KidneyIntelX uses machine learning to turn messy real world kidney data into practical risk scores that clinicians and drug developers can use. The stock offers exposure to precision diagnostics in chronic kidney disease and to the broader push to use AI to sharpen trial design and patient management. One unresolved dependency could heavily influence how that AI opportunity translates into future economics.
AIM:RENX Earnings & Revenue History as at Nov 2026
Abingdon Health runs a broad diagnostics operation. What ties it into AI powered healthcare is Appdx, the smartphone reader software that turns lateral flow tests into digitized results that can be used for remote monitoring and data rich clinical workflows.
Abingdon Health generates about £5 million from contract development, £4.1 million from regulatory work, £1.3 million from contract manufacturing and £0.6 million from product sales, and the stock carries a market value of roughly £39 million.
That combination of AI enabled diagnostics and full service support positions Abingdon Health squarely inside this screener. The real intrigue lies in how one future shift could reshape the economics of those contracts.
“Broader adoption of rapid point of care and self testing across multiple therapy areas is creating more demand for lateral flow based companion diagnostics. Abingdon’s end to end CDMO and regulatory capabilities can support larger, longer duration programs and potentially raise revenue visibility and earnings quality.”
What happens if that pressure point breaks in Abingdon Health’s favor is the question that could matter most for your margins and growth expectations.
If that shift plays out the way you are imagining, read the full narrative for Abingdon Health to see what could be accelerating or capping Abingdon Health’s upside.
AIM:ABDX Revenue & Expenses Breakdown as at Nov 2026
AstraZeneca is a global biopharma group based in Cambridge that develops prescription medicines across oncology, cardiovascular, respiratory, vaccines, immune therapies, and rare diseases. It generates about US$62.4b from pharmaceuticals, with a roughly £216.1b market cap, and AI driven oncology R&D as a key theme link.
AstraZeneca is already a heavyweight in cancer and rare disease treatments, which makes its AI partnerships especially important for this screener. The interest here is less about a single drug and more about how AI fed pipelines can reshape how quickly complex medicines reach patients.
“The company’s robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular or metabolic therapies, is now underpinned by management’s disclosure of 12 programs each with risk adjusted peak sales potential above US$5b and several more in the US$3b to US$5b range.”
The key unknown is what happens if one quiet assumption about how efficiently AI can compress development timelines and costs proves too conservative, as this is where the real torque could sit.
If that upside scenario is even half right, read the full narrative for AstraZeneca to see how AstraZeneca’s AI work could be accelerating more than headline pipelines suggest.
LSE:AZN Earnings & Revenue Growth as at Nov 2026
Seeking Alternatives Before The Crowd?
Fresh ideas move first. Breakout stories build momentum while they are still under the radar for now, and late entries get caught chasing dropping odds. Act now.
Target durable cash generators by scanning a curated 4 dividend fortresses and spot potential income anchors before yields start flying lower for new buyers.
Race ahead of mainstream attention by tracking under-followed businesses in the 5 high quality undiscovered gems and position yourself while interest is still building.
Ride the backbone of the AI buildout using the 53 AI infrastructure stocks and focus on enablers that could gain strength as demand compounds.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Leave a comment